Corrected Survey on the SUPPORT Act's Prescription Drug Monitoring Program Mandate
We want to inform you that we encountered technical issues with the survey regarding the SUPPORT Act's PDMP mandate. We apologize for any inconvenience this may have caused. If you attempted to take the survey previously, please try again. If you have not participated yet, we encourage you to take the survey now. Your feedback is essential in helping us assess the implementation of this mandate. The survey will take approximately 5 minutes, and your responses will remain confidential. To access the survey, please click here.
Thank you for your understanding and your continued support.
MO HealthNet is conducting a survey regarding the implementation of the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities (SUPPORT) Act's prescription drug monitoring program mandate.
The SUPPORT Act, signed into law on October 24, 2018, required that states mandate that covered providers consult a qualified prescription drug monitoring program (PDMP) before prescribing controlled substances to covered individuals. Moreover, beginning with the Federal Fiscal Year (FFY) 2023, states must report annual data about the use of PDMPs by covered providers before prescribing controlled substances to the Department of Health and Human Services (HHS).
To help assess the implementation of this mandate, we would appreciate your participation in this survey. The survey should take 5 minutes, and your responses will be confidential.
To participate in the survey, please click here.
MO HealthNet appreciates your participation.